Parexel discusses transdermal drug delivery techs

This content item was originally published on www.biopharma-reporter.com, a William Reed online publication.

By Natalie Morrison

- Last updated on GMT

Related tags: Pharmacology

Electroporation is the wave of the future for transdermal drug delivery, according to Parexel’s Ravi Harapanhalli.

The contract research organisation’s (CRO) principle consultant for late stage development told in-PharmaTechnologist that, with recent developments, it is an exciting time for delivery via the skin.

“The industry is at a stage where hydrophilic drugs, peptides, heparin fragments and even proteins can be delivered through the skin,”​ said Harapanhalli.

“This is a big development in the design and control of drugs.”

Put to Harapanhalli the question of the next ‘big thing’ in the research area, he said that electroporation shows promise.

He added: “I must say electroporosis – passage of low voltage electric current through the patch (is promising).

“The method is commonly used in development at the moment, and there are some approved products already using that technology and they are able to achieve better controlled and more effective delivery.”

Related news

Show more

Related products

show more

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Curia | 15-Nov-2021 | Technical / White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created...

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Related suppliers

Follow us

Products

View more

Webinars